RxDoctor Payments Data

Bryan Bruner, MD

Urology · Grapevine, TXNPI 1043439920

Payments from drug & device makers

$7,746in general payments, 2019–2025

Across 358 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$730
  • Sumitomo Pharma America, Inc.$727
  • Dendreon Pharmaceuticals LLC$611
  • Astellas Pharma US Inc$534
  • Pfizer$519
  • Boston Scientific$420
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$7,64799%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,746 in reported general payments places this provider in the 65th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$620,687
Medicare patients
1,033
Services billed
7,222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix214$550,894
NubeqaDarolutamide12$163,716
MyrbetriqMirabegron103$91,457
GemtesaVibegron100$79,616
Tamsulosin Hcl771$12,112
Solifenacin Succinate171$7,410
Silodosin78$6,494
Testosterone16$4,154
Dutasteride89$3,633
NitrofurantoinNitrofurantoin Macrocrystal102$2,637
Finasteride140$2,236
Testosterone Cypionate36$1,686
Oxybutynin Chloride ErOxybutynin Chloride66$1,410
Potassium Citrate ErPotassium Citrate25$1,260
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen136$824

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$727$630,510314 claims
BayerNubeqa$197$163,71612 claims
Astellas Pharma US IncMyrbetriq$534$91,457103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 878 urology providers in Texas.

Other urology in Grapevine

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →